Personalized Cancer Vaccines

The Federal Republic of Brandenburg, Germany with its ProFIT Brandenburg Program and the European Union via its European Regional Development Fund (ERDF), supports with 1 Million USD, the development of peptides & elephants' exclusive high parallel Ultrasound Peptide Synthesis, USPS®.  This state-of-the-art technology will be used to develop personalized vaccines in the treatment of cancer. 

Within 2021, peptides & elephants will complete production of the prototype USPS® synthesizer, in accordance with all GMP regulations. The synthesizer will be able to produce hundreds of peptides within a few hours. USPS® will allow a wide application in personalized cancer therapeutics as for the first time it will be possible to get enough affordable personalized peptide cancer vaccines to treat an unlimited number of patients.

The fields marked with * are required.